← Leaderboards
Asad Bashey
Northside Hospital Atlanta
$969,175
Attributed
$1,683,125
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $156.3K · FY2011–23$200K$150K$100K$50K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,683,125 · 2
By mechanism
UG1$1,070,925 · 1
U10$612,200 · 1
Top collaborators
- Edward A. Copelan7 shared
- Krishna V. Komanduri7 shared
Most similar at Northside Hospital Atlanta
Same institution · by research overlap
- Edward A. Copelan$356,975
Others in their field
Top investigators on “Cost”
- Eric S Lander · Whitehead Institute For Biomedical Res$748,368,930
- Richard K. Wilson · Washington University$429,230,873
- Richard A Gibbs · Baylor College Of Medicine$414,258,216
- David R. Weir · University Of Michigan At Ann Arbor$393,741,481
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
Research focus
CostNovel StrategiesPilot TrialRelapseChronic Graft Versus Host DiseaseTransplantationMinorityRandomizedRaceRegimenConditioningSiblingsHematopoieticToxic EffectCyclophosphamideMalignant NeoplasmsAllogenicHematopoietic Cell TransplantationSafetyEthnic Minority PopulationPhase Ii TrialStandard Of CareMortalityAntibodies
Grant awards (13)
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$152,051
UG1 · FY2023 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$153,075
UG1 · FY2022 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$154,100
UG1 · FY2021 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$155,199
UG1 · FY2020 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$156,263
UG1 · FY2019 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$149,563
UG1 · FY2018 · HL · contact PI
Reduction of Relapse Risk Through Incorporation of Novel Biologic Agents Following Reduced Intensity Haploidentical Donor Transplant for Acute Myeloid Leukemia.$150,674
UG1 · FY2017 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$100,668
U10 · FY2016 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$103,500
U10 · FY2015 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$103,500
U10 · FY2014 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$103,500
U10 · FY2013 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$103,500
U10 · FY2012 · HL · contact PI
Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD$97,532
U10 · FY2011 · HL · contact PI